http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003118597-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0003 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-35 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-35 |
| filingDate | 2002-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d08f59e45a46b766b2dcc3db939e1fc9 |
| publicationDate | 2003-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2003118597-A1 |
| titleOfInvention | Process for production of bee venom as pharmaceutical product which can be used effectively in the treatment of rheumatoid arthritis and viral diseases |
| abstract | The traditional treatment for Rheumatoid Arthritis relies on a course of synthetic drugs, which range from the use of gold salts to anti-inflammatory drugs including both steroids and non-steroids. These drugs specially the steroids can affect adrenal and pituitary glands & cause impotence, edema, poor wound healing, reduce neurological response and cardiac irregularities. n VACSERA began the first clinical studies with bee venom therapy and proved its efficiency for treatment of variety of diseases such as Rheumatoid arthritis and viral infections especially (HCV). Bee Venom was separated by a scientific method and then we determine the dosage form, toxicity, bioavailability, teratogenicity, (anti-teratogenic effect), safety and treatment schedule. n The use of Bee venom in treatment of arthritis has been proved to be beneficial to many patients, primarily due to the presence of a number of polypeptides, peptides, enzymes and amines. The venom is administered according to the enclosed leaflet and physician instructions in doses which vary according to the disease and its severity. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7527817-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100744755-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10232048-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105738516-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007114575-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005013912-A1 |
| priorityDate | 2001-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 185.